trending Market Intelligence /marketintelligence/en/news-insights/trending/yauyzl-IgopjuotqGnHrgw2 content esgSubNav
In This List

Novartis applications for Tafinlar, Mekinist accepted by Chinese regulators

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Novartis applications for Tafinlar, Mekinist accepted by Chinese regulators

Novartis AG's marketing applications for skin cancer drugs Tafinlar and Mekinist were accepted by Chinese regulators, according to the country's Center for Drug Evaluation.

Tafinlar, also known as dabrafenib, inhibits a gene called BRAF, which can mutate and drive certain cancers. Mekinist, also known as trametinib, inhibits the MEK 1 and MEK 2 protein in cancer cells.

The U.S. Food and Drug Administration in 2013 approved Tafinlar and Mekinist as treatments for advanced melanoma, and later approved the drugs as a combination therapy for melanoma with BRAF V600E or V600K mutations, thyroid cancer and non-small cell lung cancer.

GlaxoSmithKline PLC developed Tafinlar and Mekinist, which were obtained by Novartis as part of its acquisition of GSK's oncology business in 2015.